• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The 2024 Guidelines for Osteoporosis - Korean Society of Menopause: Part II.

作者信息

Lee Dong Ock, Hong Yeon Hee, Cho Moon Kyoung, Choi Young Sik, Chun Sungwook, Chung Youn-Jee, Hong Seung Hwa, Hwang Kyu Ri, Kim Jinju, Kim Hoon, Lee Dong-Yun, Lee Sa Ra, Park Hyun-Tae, Seo Seok Kyo, Shin Jung-Ho, Song Jae Yen, Yi Kyong Wook, Paik Haerin, Lee Ji Young

机构信息

Center for Gynecologic Cancer, National Cancer Center, Goyang, Korea.

Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.

出版信息

J Menopausal Med. 2024 Aug;30(2):55-77. doi: 10.6118/jmm.300001.

DOI:10.6118/jmm.300001
PMID:39315499
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11439573/
Abstract
摘要

相似文献

1
The 2024 Guidelines for Osteoporosis - Korean Society of Menopause: Part II.《2024年骨质疏松症指南 - 韩国更年期协会：第二部分》
J Menopausal Med. 2024 Aug;30(2):55-77. doi: 10.6118/jmm.300001.
2
Corrigendum: 2023 Korean Society of Menopause - Osteoporosis Guidelines Part I.勘误：2023年韩国更年期学会 - 骨质疏松症指南 第一部分。
J Menopausal Med. 2024 Aug;30(2):126. doi: 10.6118/jmm.300002.
3
The 2024 Guidelines for Osteoporosis - Korean Society of Menopause: Part I.《2024年骨质疏松症指南——韩国更年期协会：第一部分》
J Menopausal Med. 2024 Apr;30(1):1-23. doi: 10.6118/jmm.24000.
4
The 2017 hormone therapy position statement of The North American Menopause Society.《北美绝经学会 2017 年激素治疗立场声明》。
Menopause. 2018 Nov;25(11):1362-1387. doi: 10.1097/GME.0000000000001241.
5
2013 Up-date of the consensus statement of the Spanish Menopause Society on postmenopausal osteoporosis.2013 年西班牙绝经学会绝经后骨质疏松症共识声明更新。
Maturitas. 2013 Sep;76(1):99-107. doi: 10.1016/j.maturitas.2013.05.021. Epub 2013 Jul 1.
6
The 2017 hormone therapy position statement of The North American Menopause Society.北美更年期协会2017年激素治疗立场声明。
Menopause. 2017 Jul;24(7):728-753. doi: 10.1097/GME.0000000000000921.
7
Vasomotor symptoms and osteoporosis in Korean postmenopausal women.韩国绝经后女性的血管舒缩症状与骨质疏松症
Maturitas. 2016 May;87:27-32. doi: 10.1016/j.maturitas.2016.02.007. Epub 2016 Feb 12.
8
The adherence to practice guidelines in the assessment of bone health in women with chemotherapy-induced menopause.化疗所致绝经女性骨健康评估中对实践指南的遵循情况
J Support Oncol. 2006 Jun;4(6):295-8, 304.
9
European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis.欧洲绝经学会（EMAS）和国际妇科肿瘤学会（IGCS）关于妇科癌症后管理绝经的立场声明：关注绝经症状和骨质疏松症。
Maturitas. 2020 Apr;134:56-61. doi: 10.1016/j.maturitas.2020.01.005. Epub 2020 Feb 11.
10
Association between osteoporosis and periodontal disease among menopausal women: The 2013-2015 Korea National Health and Nutrition Examination Survey.绝经后妇女骨质疏松症与牙周病的相关性：2013-2015 年韩国国家健康与营养检查调查。
PLoS One. 2022 Mar 17;17(3):e0265631. doi: 10.1371/journal.pone.0265631. eCollection 2022.

本文引用的文献

1
Interventions for managing medication-related osteonecrosis of the jaw.干预措施管理与药物相关的颌骨坏死。
Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD012432. doi: 10.1002/14651858.CD012432.pub3.
2
Teriparatide: Label changes and identifying patients for long-term use.特立帕肽：标签变更及长期使用患者的识别
Cleve Clin J Med. 2021 Sep 1;88(9):489-493. doi: 10.3949/ccjm.88a.21011.
3
Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society.绝经后女性骨质疏松症的管理：北美更年期协会2021年立场声明
Menopause. 2021 Sep 1;28(9):973-997. doi: 10.1097/GME.0000000000001831.
4
Bisphosphonates after denosumab withdrawal reduce the vertebral fractures incidence.地诺单抗停药后使用双膦酸盐可降低椎体骨折发生率。
Eur J Endocrinol. 2021 Aug 4;185(3):387-396. doi: 10.1530/EJE-21-0157.
5
Romosozumab: A Review in Postmenopausal Osteoporosis.罗莫佐单抗：用于绝经后骨质疏松症的研究综述。
Drugs Aging. 2020 Nov;37(11):845-855. doi: 10.1007/s40266-020-00793-8.
6
Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment.唑来膦酸序贯治疗可以避免因停用少于 3 年的地舒单抗治疗而产生的弊端。
J Bone Miner Metab. 2020 Nov;38(6):894-902. doi: 10.1007/s00774-020-01126-w. Epub 2020 Jul 12.
7
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE.美国临床内分泌医师协会/美国内分泌学会 2020 年绝经后骨质疏松症诊断和治疗临床实践指南更新版
Endocr Pract. 2020 May;26(Suppl 1):1-46. doi: 10.4158/GL-2020-0524SUPPL.
8
Comparison between teriparatide and bisphosphonates for improving bone mineral density in postmenopausal osteoporosis patients: A meta-analysis.特立帕肽与双膦酸盐类药物在改善绝经后骨质疏松症患者骨密度方面的比较：一项荟萃分析。
Medicine (Baltimore). 2020 Apr;99(15):e18964. doi: 10.1097/MD.0000000000018964.
9
Sarcopenia Definition: The Position Statements of the Sarcopenia Definition and Outcomes Consortium.肌肉减少症定义：肌肉减少症定义和结局共识联盟的立场声明。
J Am Geriatr Soc. 2020 Jul;68(7):1410-1418. doi: 10.1111/jgs.16372. Epub 2020 Mar 9.
10
Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment.亚洲肌少症工作组：2019年肌少症诊断与治疗共识更新
J Am Med Dir Assoc. 2020 Mar;21(3):300-307.e2. doi: 10.1016/j.jamda.2019.12.012. Epub 2020 Feb 4.